Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Edge Reaches Deal with America's Choice Provider Network

NEW YORK (GenomeWeb News) – Pacific Edge today announced it has signed on payor America's Choice Provider Network, expanding access to its bladder cancer test.

ACPN's clients include contracted insurance carriers, third-party administrators, health and welfare funds, employer groups, and self-insured health plans. According to Pacific Edge, 14 million patients in ACPN's network now will have access to its Cxbladder test.

The test is urine-based and comprises five biomarkers. It identifies patients with changes in gene expression and helps rule out cancer in patients with normal gene expression. It will be run out of the CLIA-certified laboratory of Pacific Edge's US subsidiary, Pacific Edge Diagnostics USA, in Hershey, Pa.

Financial and other terms of the agreement with ACPN were not disclosed.

Today's deal follows a recent agreement between the New Zealand-based cancer diagnostics company and preferred provider organization FedMed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.